Sandoz' Biosimilar Etanercept On Its Way To EU Market
This article was originally published in Scrip
Executive Summary
The EMA has accepted for review a biosimilar etanercept product from Novartis's Sandoz division. The biosimilar version of Pfizer's TNF-inhibitor Enbrel has been filed for use in all the indications detailed in Enbrel's label, including rheumatoid arthritis and psoriasis.
You may also be interested in...
Sandoz Extrapolates Biosimilar Rituximab Data For EU Filing
Sandoz has used data extrapolation to all the indications for Roche's MabThera in its marketing submission for biosimilar rituximab, just accepted for review by the European Medicines Agency.
Sandoz Extrapolates Biosimilar Rituximab Data For EU Filing
Sandoz has used data extrapolation to all the indications for Roche's MabThera in its marketing submission for biosimilar rituximab, just accepted for review by the European Medicines Agency.
Despite 'Remarkable' ROI On Women’s Health Investments, Money Still Lacking
Recent US government initiatives and growing investor interest are important for developing female-specific therapeutics, but funding is not yet where it should be.